![Dollar consolidates ahead of key inflation release; yen nears intervention](https://i-invdn-com.investing.com/news/LYNXMPED6618D_S.jpg)
Please try another search
Idenix Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in the discovery and development of drugs for the treatment of human viral diseases in the United States and France. Its primary research and development focus is on the treatment of patients with hepatitis C virus (HCV). The company’s HCV discovery program focuses on nucleoside/nucleotide polymerase inhibitors, NS5A inhibitors, protease inhibitors, and non-nucleoside polymerase inhibitors. It is also developing non-nucleoside reverse transcriptase inhibitors for the treatment of human immunodeficiency (HIV) virus type-1 and acquired immune deficiency syndrome (AIDS); and products and drug candidates for the treatment of patients with hepatitis B virus (HBV). The company has a collaboration agreement with Janssen Pharmaceuticals, Inc.; Novartis Pharma AG; ViiV Healthcare Company; and GlaxoSmithKline. Idenix Pharmaceuticals, Inc. was formerly known as Novirio Pharmaceuticals Inc. and changed its name to Idenix Pharmaceuticals, Inc. in May 2002. Idenix Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts. As of August 4, 2014, Idenix Pharmaceuticals, Inc. operates as a subsidiary of Merck & Co., Inc.
Name | Age | Since | Title |
---|---|---|---|
Adrian Di Bisceglie | - | - | Member of Hepatitis Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review